Sanofi Pasteur to accelerate vaccine uptake with partnership
This article was originally published in Scrip
Executive Summary
Sanofi Pasteur is to promote its experimental dengue fever vaccine, the first to enter Phase III development, by partnering with the International Vaccine Institute (IVI). The collaboration will focus on accelerating uptake of the vaccine, says IVI's chairman of the board of trustees, Dr Ragnar Norrby.